The pharma sector opens Monday, October 5, with a mixed bag of regulatory and commercial shocks. Cipla’s shares face immediate pressure after the Maharashtra FDA revoked its wholesale drug sale and distribution licence in Pune. The regulator cited specific violations regarding storage conditions and the misbranding of Reactin Plus Tablets. Cipla’s statement claims the warehouse is fully compliant, but the company is now evaluating legal options while the licence remains suspended.
On the research front, Sun Pharmaceutical Industries provided hard data on LEQSELVI for severe alopecia areata. In presentations at the 2026 EADV Congress, the company noted that 94% of patients who responded at Week 52 sustained that response through Week 108. The safety profile remained consistent with prior trials, reinforcing the drug’s long-term therapeutic value.
Piramal Pharma delivered a quiet but definitive update: its commercial agreement with Bayer Pharma expires on December 31, 2026, and will not be renewed. The deal covered sales and distribution support, contributing to commission income. However, the company clarified this stream accounted for less than 5% of consolidated revenue, meaning the exit is unlikely to dent bottom-line profits materially.
Aurobindo Pharma is expanding its footprint through acquisition. Its subsidiary, Apitoria Pharma, is buying the Contract Research Services business of A1 Biochem Group. The structure involves A1 Biochem USA acquiring 100% of US-based A1 Biochem Labs LLC, which will sit as a step-down subsidiary under A1 Biochem Labs India. This move signals Aurobindo’s continued push into the CRAMS segment.